Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Tivantinib

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    4 result(s) found for: Tivantinib. Displaying page 1 of 1.
    EudraCT Number: 2012-005578-79 Sponsor Protocol Number: ONC-2012-001 Start Date*: 2013-02-09
    Sponsor Name:ISTITUTO CLINICO HUMANITAS
    Full Title: A single-Arm Phase II Study of Tivantinib (ARQ 197) plus Cetuximab in EGFR inhibitor-resistant MET high subjects with locally advanced or metastatic colorectal cancer with wild-type KRAS
    Medical condition: Patients with advanced or metastatic wild type CRAS, MET high, CRC who have progressed on a previous EGFR inibitor based regimen
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10017990 Malignant and unspecified neoplasms gastrointestinal NEC HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002497-37 Sponsor Protocol Number: IOV-SCLC-1-2014-TIMES Start Date*: 2014-12-22
    Sponsor Name:Istituto Oncologico del Veneto IRCCS – UOC Oncologia Medica 2
    Full Title: TIvantinib as Maintenance treatment in Extended Small-cell lung cancer (TIMES) Phase II clinical trial, single arm, two stage
    Medical condition: Small Cell Lung Cancer (SCLC) after first-line platinum plus etoposide therapy
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041068 Small cell lung cancer extensive stage PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-003308-10 Sponsor Protocol Number: ARQ197-A-U303 Start Date*: 2012-12-20
    Sponsor Name:DAIICHI SANKIO DEVELOPMENT LIMITED
    Full Title: A Phase 3, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects with MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC) Treated with One Prior Systemic Therapy
    Medical condition: MET Diagnostic-High Inoperable Hepatocellular Carcinoma (HCC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10019828 Hepatocellular carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) SE (Prematurely Ended) BE (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) PT (Prematurely Ended) NL (Completed) ES (Completed) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001238-32 Sponsor Protocol Number: ADVL1622 Start Date*: 2019-09-26
    Sponsor Name:National Cancer Institute Cancer Therapy Evaluation
    Full Title: Phase 2 Trial of XL184 (Cabozantinib) an Oral Small-Molecule Inhibitor of Multiple Kinases, in Children and Young Adults with Refractory Sarcomas, Wilms Tumor, and Other Rare Tumors
    Medical condition: Ewing sarcoma, Rhabdomyosarcoma, Non rhabdomyosarcoma, Wilms Tumor, Osteosarcoma and Other Rare Tumors
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 20 14:06:59 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA